STAT3 expression in activating EGFR-driven adenocarcinoma of the lung

Lung Cancer

Volumn 75, Issue 1, 2012, Pages 24-29

  Takata, Saburo ^a   Takigawa, Nagio ^d   Segawa, Yoshihiko ^b   Kubo, Toshio ^a   Ohashi, Kadoaki ^a   Kozuki, Toshiyuki ^b   Teramoto, Norihiro ^c   Yamashita, Motohiro ^c   Toyooka, Shinichi ^c   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; Bronchioloalveolar carcinoma; EGFR; JAK2; Non small cell lung cancer; STAT3

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 83555174457     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.05.015     Document Type: Article

References (28)

1. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
2. William W.N., Lin H.Y., Lee J.J., Lippman S.M., Roth J.A., Kim E.S. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009.
3. Kerr K.M., Carey F.A., King G., Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J Pathol 1994, 174:249-256.
4. Okada M., Nishio W., Sakamoto T., Uchino K., Hanioka K., Ohbayashi C., et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg 2004, 127:857-861.
5. Noguchi M., Morikawa A., Kawasaki M., Matsuno Y., Yamada T., Hirohashi S., et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995, 75:2844-2852.
6. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355:1763-1771.
7. Travis W.D., Garg K., Franklin W.A., Wistuba I.I., Sabloff B., Noguchi M., et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005, 23:3279-3287.
8. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
9. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006, 20:1496-1510.
10. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9:485-495.
11. Ohashi K., Rai K., Fujiwara Y., Osawa M., Hirano S., Takata K., et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci 2008, 99:1747-1753.
12. Kozuki T., Hisamoto A., Tabata M., Takigawa N., Kiura K., Segawa Y., et al. Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer 2007, 58:30-35.
13. Yan C., Naltner A., Martin M., Naltner M., Fangman J.M., Gurel O. Transcriptional stimulation of the surfactant protein B gene by STAT3 in respiratory epithelial cells. J Biol Chem 2002, 277:10967-10972.
14. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
15. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., Frank D.A. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006, 66:3162-3168.
16. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003, 63:1270-1279.
17. Cappuzzo F., Magrini E., Ceresoli G.L., Bartolini S., Rossi E., Ludovini V., et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:1133-1141.
18. Asano H., Toyooka S., Tokumo M., Ichimura K., Aoe K., Ito S., et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006, 12:43-48.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
20. Haura E.B., Zheng Z., Song L., Cantor A., Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005, 11:8288-8294.
21. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856.
22. Li Y., Du H., Qin Y., Roberts J., Cummings O.W., Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007, 67:8494-8503.
23. Achcar Rde O., Cagle P.T., Jagirdar J. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch Pathol Lab Med 2007, 131:1350-1360.
24. Song L., Turkson J., Karras J.G., Jove R., Haura E.B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22:4150-4165.
25. Zimmer S., Kahl P., Buhl T.M., Steiner S., Wardelmann E., Merkelbach-Bruse S., et al. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol 2009, 135:723-730.
26. Nakanishi H., Matsumoto S., Iwakawa R., Kohno T., Suzuki K., Tsuta K., et al. Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res 2009, 69:1615-1623.
27. Garber K. JAK2 inhibitors: not the next imatinib but researchers see other possibilities. J Natl Cancer Inst 2009, 101:980-982.
28. Sen B., Saigal B., Parikh N., Gallick G., Johnson F.M. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 2009, 69:1958-1965.